Ascendis Pharma ADR (ASND)

$194.30 +1.50 (0.78%)
Market Cap 11.89B
Revenue (ttm) 393.50M
Net Income (ttm) -409.12M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -103.97%
Debt to Equity Ratio -4.23
Volume 308,100
Avg Vol 480,612
Day's Range N/A - N/A
Shares Out 61.21M
Stochastic %K 63%
Beta 0.41
Analysts Strong Sell
Price Target $251.38

Company Profile

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candid...

Industry: Biotechnology
Sector: Healthcare
Phone: 45 70 22 22 44
Address:
Tuborg Boulevard 12, Hellerup, Denmark
tymtested
tymtested Aug. 23 at 3:59 PM
$ASND is this Denmark company still reporting huge quarterly losses??
0 · Reply
AP530
AP530 Aug. 20 at 2:03 PM
$ASND surprised this hasn’t hit over $200 yet. Was so close too
0 · Reply
TrendEdgeLogan
TrendEdgeLogan Aug. 16 at 4:14 PM
$XBI $IBB $ONC $CNTA $ASND
1 · Reply
JFDI
JFDI Aug. 14 at 3:42 PM
$ASND ABCD
0 · Reply
pugmarkettt
pugmarkettt Aug. 13 at 3:17 PM
$ASND ascend Deez nuts already
0 · Reply
Pika_Capital
Pika_Capital Aug. 12 at 6:39 PM
$ASND you can NOT stop $200 from coming. Let's go baby!!
1 · Reply
Doozio
Doozio Aug. 10 at 6:02 PM
$GILD it was always during 🐒🍌🧠⏰♾️ wen da huckleberries would $ASND thru the $$$$ as 🧠leader🐑 is becoming obviously obvious. 🐑 $XBI shall follow.
0 · Reply
JarvisFlow
JarvisFlow Aug. 8 at 11:00 PM
Citigroup has updated their rating for Ascendis Pharma ( $ASND ) to Buy with a price target of 290.
0 · Reply
Pika_Capital
Pika_Capital Aug. 8 at 5:04 PM
$ASND can't believe I snatched some shares at $179 today 😂
2 · Reply
JarvisFlow
JarvisFlow Aug. 8 at 4:07 PM
Wedbush has adjusted their stance on Ascendis Pharma ( $ASND ), setting the rating to Outperform with a target price of 212 → 220.
0 · Reply
Latest News on ASND
Ascendis Pharma A/S (ASND) Q2 2025 Earnings Call Transcript

Aug 9, 2025, 2:46 AM EDT - 16 days ago

Ascendis Pharma A/S (ASND) Q2 2025 Earnings Call Transcript

Ascendis Pharma Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 4:01 PM EDT - 17 days ago

Ascendis Pharma Reports Second Quarter 2025 Financial Results

Ascendis Pharma to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025

Jul 31, 2025, 4:01 PM EDT - 24 days ago

Ascendis Pharma to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025

FDA Approves SKYTROFA® (Lonapegsomatropin-tcgd) for the Once-Weekly Treatment of Adults with Growth Hormone Deficiency

Jul 28, 2025, 7:00 AM EDT - 4 weeks ago

FDA Approves SKYTROFA® (Lonapegsomatropin-tcgd) for the Once-Weekly Treatment of Adults with Growth Hormone Deficiency

New 3-Year Phase 3 Data Confirmed Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism, Including Improvements in Biochemistries, Kidney Function, and Quality of Life

Jul 14, 2025, 4:01 PM EDT - 5 weeks ago

New 3-Year Phase 3 Data Confirmed Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism, Including Improvements in Biochemistries, Kidney Function, and Quality of Life

Ascendis to Share Its Latest Endocrinology Rare Disease Data at ENDO 2025

Jul 7, 2025, 4:01 PM EDT - 6 weeks ago

Ascendis to Share Its Latest Endocrinology Rare Disease Data at ENDO 2025

TransCon® hGH Boosted Treatment Benefits of TransCon® CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH Trial

Jun 9, 2025, 7:00 AM EDT - 2 months ago

TransCon® hGH Boosted Treatment Benefits of TransCon® CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH Trial

FDA Accepts TransCon® CNP NDA for Priority Review

Jun 2, 2025, 8:00 AM EDT - 2 months ago

FDA Accepts TransCon® CNP NDA for Priority Review

Cerrado Gold and Ascendant Resources Announce Completion of Business Combination Transaction

May 20, 2025, 6:00 AM EDT - 3 months ago

Cerrado Gold and Ascendant Resources Announce Completion of Business Combination Transaction

New Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon® CNP (Navepegritide)

May 13, 2025, 4:01 PM EDT - 3 months ago

New Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon® CNP (Navepegritide)

New 4-Year Data Shows Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism

May 12, 2025, 4:45 PM EDT - 3 months ago

New 4-Year Data Shows Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism

Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE & ESE 2025

May 5, 2025, 8:30 AM EDT - 3 months ago

Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE & ESE 2025

Ascendis Pharma A/S (ASND) Q1 2025 Earnings Call Transcript

May 1, 2025, 9:35 PM EDT - 4 months ago

Ascendis Pharma A/S (ASND) Q1 2025 Earnings Call Transcript

Ascendis Pharma Reports First Quarter 2025 Financial Results

May 1, 2025, 4:01 PM EDT - 4 months ago

Ascendis Pharma Reports First Quarter 2025 Financial Results

Ascendis Pharma to Report First Quarter 2025 Financial Results and Provide Business Update on May 1, 2025

Apr 24, 2025, 4:01 PM EDT - 4 months ago

Ascendis Pharma to Report First Quarter 2025 Financial Results and Provide Business Update on May 1, 2025

Ascendis Pharma: Rare Disease Player Is A Buy On Yorvipath Launch Trajectory

Apr 14, 2025, 4:38 PM EDT - 4 months ago

Ascendis Pharma: Rare Disease Player Is A Buy On Yorvipath Launch Trajectory

Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia

Mar 31, 2025, 4:01 PM EDT - 5 months ago

Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia

Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care Conference

Feb 24, 2025, 4:01 PM EST - 6 months ago

Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care Conference

Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday?

Feb 13, 2025, 2:40 PM EST - 6 months ago

Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday?

Ascendis Pharma A/S (ASND) Q4 2024 Earnings Call Transcript

Feb 12, 2025, 11:03 PM EST - 6 months ago

Ascendis Pharma A/S (ASND) Q4 2024 Earnings Call Transcript

Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs

Feb 12, 2025, 4:05 PM EST - 6 months ago

Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs

Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 12, 2025, 4:01 PM EST - 6 months ago

Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results

Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025

Feb 5, 2025, 4:01 PM EST - 7 months ago

Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025

Ascendis-Novo Weight Loss Deal Highlights Technology Platform, Signals Growth Potential (Rating Upgrade)

Jan 29, 2025, 11:25 AM EST - 7 months ago

Ascendis-Novo Weight Loss Deal Highlights Technology Platform, Signals Growth Potential (Rating Upgrade)

Ascendis Pharma: Danish Blockbuster Hunter

Jan 29, 2025, 12:31 AM EST - 7 months ago

Ascendis Pharma: Danish Blockbuster Hunter

Ascendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare Conference

Jan 12, 2025, 5:00 PM EST - 8 months ago

Ascendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare Conference

Ascendis Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 8:30 AM EST - 8 months ago

Ascendis Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

YORVIPATH® (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in Adults

Dec 19, 2024, 8:30 AM EST - 8 months ago

YORVIPATH® (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in Adults

New InsiGHTS Trial of TransCon™ hGH (Lonapegsomatropin) in Turner Syndrome Achieved Primary Objective at Week 26

Dec 16, 2024, 8:30 AM EST - 8 months ago

New InsiGHTS Trial of TransCon™ hGH (Lonapegsomatropin) in Turner Syndrome Achieved Primary Objective at Week 26

FDA Accepts Ascendis Pharma's Supplemental Biologics License Application for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency

Dec 12, 2024, 4:01 PM EST - 9 months ago

FDA Accepts Ascendis Pharma's Supplemental Biologics License Application for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency

Er-Kim Extends Exclusive Distribution Agreement with Ascendis Pharma A/S to Expand Commercialization of Its Endocrinology Portfolio to Eurasian Markets

Dec 10, 2024, 7:00 AM EST - 9 months ago

Er-Kim Extends Exclusive Distribution Agreement with Ascendis Pharma A/S to Expand Commercialization of Its Endocrinology Portfolio to Eurasian Markets

Ascendis Pharma A/S (ASND) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 10:53 PM EST - 10 months ago

Ascendis Pharma A/S (ASND) Q3 2024 Earnings Call Transcript

Ascendis Pharma Reports Third Quarter 2024 Financial Results

Nov 14, 2024, 4:01 PM EST - 10 months ago

Ascendis Pharma Reports Third Quarter 2024 Financial Results

Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency

Sep 30, 2024, 8:30 AM EDT - 11 months ago

Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency

New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide) Presented at ASBMR 2024

Sep 30, 2024, 8:30 AM EDT - 11 months ago

New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide) Presented at ASBMR 2024

Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs

Sep 19, 2024, 8:16 PM EDT - 1 year ago

Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs

Ascendis Pharma A/S Announces Proposed Public Offering of ADSs

Sep 18, 2024, 4:04 PM EDT - 1 year ago

Ascendis Pharma A/S Announces Proposed Public Offering of ADSs

Ascendis Pharma's Rare Dwarfism Candidate Shows Promise In Trial, FDA Submission Expected Next Year

Sep 16, 2024, 12:18 PM EDT - 1 year ago

Ascendis Pharma's Rare Dwarfism Candidate Shows Promise In Trial, FDA Submission Expected Next Year

Pivotal ApproaCH Trial of TransCon™ CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo

Sep 16, 2024, 7:00 AM EDT - 1 year ago

Pivotal ApproaCH Trial of TransCon™ CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo

Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort of the Phase 1/2 IL-Believe Trial at ESMO 2024

Sep 13, 2024, 8:30 AM EDT - 1 year ago

Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort of the Phase 1/2 IL-Believe Trial at ESMO 2024

Ascendis Pharma Receives Orphan Drug Exclusivity in the U.S. for YORVIPATH® (Palopegteriparatide) for the Treatment of Hypoparathyroidism in Adults

Sep 11, 2024, 5:37 PM EDT - 1 year ago

Ascendis Pharma Receives Orphan Drug Exclusivity in the U.S. for YORVIPATH® (Palopegteriparatide) for the Treatment of Hypoparathyroidism in Adults

Ascendis Pharma Takes A Big Price Cut On Skytrofa

Sep 5, 2024, 1:30 AM EDT - 1 year ago

Ascendis Pharma Takes A Big Price Cut On Skytrofa

Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In

Sep 4, 2024, 5:02 PM EDT - 1 year ago

Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In

Rare Disease-Focused Ascendis Pharma Stock Falls On Underwhelming Q2 Earnings, Guidance Cut

Sep 4, 2024, 9:09 AM EDT - 1 year ago

Rare Disease-Focused Ascendis Pharma Stock Falls On Underwhelming Q2 Earnings, Guidance Cut

Ascendis Pharma A/S (ASND) Q2 2024 Earnings Call Transcript

Sep 3, 2024, 9:41 PM EDT - 1 year ago

Ascendis Pharma A/S (ASND) Q2 2024 Earnings Call Transcript

Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement

Sep 3, 2024, 5:06 PM EDT - 1 year ago

Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement

Ascendis Pharma Reports Second Quarter 2024 Financial Results

Sep 3, 2024, 5:04 PM EDT - 1 year ago

Ascendis Pharma Reports Second Quarter 2024 Financial Results

Ascendis Pharma to Report Second Quarter 2024 Financial Results and Provide Business Update on September 3, 2024

Aug 28, 2024, 8:30 AM EDT - 1 year ago

Ascendis Pharma to Report Second Quarter 2024 Financial Results and Provide Business Update on September 3, 2024

Ascendis Pharma: Yorvipath Approved, Launch Delayed, Many Other Updates Coming Up

Aug 13, 2024, 5:25 AM EDT - 1 year ago

Ascendis Pharma: Yorvipath Approved, Launch Delayed, Many Other Updates Coming Up

Ascendis Pharma's stock surges after FDA approval for first and only treatment for rare disease

Aug 12, 2024, 8:51 AM EDT - 1 year ago

Ascendis Pharma's stock surges after FDA approval for first and only treatment for rare disease

tymtested
tymtested Aug. 23 at 3:59 PM
$ASND is this Denmark company still reporting huge quarterly losses??
0 · Reply
AP530
AP530 Aug. 20 at 2:03 PM
$ASND surprised this hasn’t hit over $200 yet. Was so close too
0 · Reply
TrendEdgeLogan
TrendEdgeLogan Aug. 16 at 4:14 PM
$XBI $IBB $ONC $CNTA $ASND
1 · Reply
JFDI
JFDI Aug. 14 at 3:42 PM
$ASND ABCD
0 · Reply
pugmarkettt
pugmarkettt Aug. 13 at 3:17 PM
$ASND ascend Deez nuts already
0 · Reply
Pika_Capital
Pika_Capital Aug. 12 at 6:39 PM
$ASND you can NOT stop $200 from coming. Let's go baby!!
1 · Reply
Doozio
Doozio Aug. 10 at 6:02 PM
$GILD it was always during 🐒🍌🧠⏰♾️ wen da huckleberries would $ASND thru the $$$$ as 🧠leader🐑 is becoming obviously obvious. 🐑 $XBI shall follow.
0 · Reply
JarvisFlow
JarvisFlow Aug. 8 at 11:00 PM
Citigroup has updated their rating for Ascendis Pharma ( $ASND ) to Buy with a price target of 290.
0 · Reply
Pika_Capital
Pika_Capital Aug. 8 at 5:04 PM
$ASND can't believe I snatched some shares at $179 today 😂
2 · Reply
JarvisFlow
JarvisFlow Aug. 8 at 4:07 PM
Wedbush has adjusted their stance on Ascendis Pharma ( $ASND ), setting the rating to Outperform with a target price of 212 → 220.
0 · Reply
JarvisFlow
JarvisFlow Aug. 8 at 3:55 PM
UBS updates rating for Ascendis Pharma ( $ASND ) to Buy, target set at 306 → 307.
0 · Reply
JarvisFlow
JarvisFlow Aug. 8 at 3:04 PM
Cantor Fitzgerald updates rating for Ascendis Pharma ( $ASND ) to Overweight, target set at 200 → 203.
0 · Reply
JarvisFlow
JarvisFlow Aug. 8 at 3:02 PM
Wells Fargo has updated their rating for Ascendis Pharma ( $ASND ) to Overweight with a price target of 295.
0 · Reply
Pika_Capital
Pika_Capital Aug. 8 at 2:30 PM
Exited $BHVN and buying $ONC $ASND since I needed cash to load up on these two puppies
0 · Reply
Pika_Capital
Pika_Capital Aug. 8 at 2:16 PM
$ASND keep selling clowns. I'm buying here
0 · Reply
JarvisFlow
JarvisFlow Aug. 8 at 1:46 PM
Stifel has updated their rating for Ascendis Pharma ( $ASND ) to Buy with a price target of 254.
0 · Reply
NJgolfer
NJgolfer Aug. 7 at 8:26 PM
$ASND revenue for Q2 up 335% compared to same period in 2024. Commercial uptake and prescribing providers exceeding expectations.
0 · Reply
Pika_Capital
Pika_Capital Aug. 7 at 8:18 PM
$ASND holy shit. Yorvipath 100m in euros in 2nd full quarter post launch. This baby is going to $250.
3 · Reply
NJgolfer
NJgolfer Aug. 7 at 8:18 PM
$ASND #Breakout underway this week to #ATHs and out of 7 week flat base that stayed above weekly @ripster47 clouds. Weekly volume already 10% higher than average. #blueskiesabove
0 · Reply
Doozio
Doozio Aug. 7 at 7:49 PM
$INCY $WGS are biotechs that act like $LGND ary 🧠leader🐑 ready to continue TTWO $ASND during 🐒🍌🧠⏰♾️
0 · Reply
Pika_Capital
Pika_Capital Aug. 7 at 6:48 PM
$ASND fomo is kicking on. 1 hr and 10 min until shit show 🍿
0 · Reply
astroplane
astroplane Aug. 7 at 3:18 PM
$ASND can any bulls tell me why the market cap is 11b here? Just for projected skytrofa sales?
0 · Reply